Literature DB >> 21415761

Compliance with periodic surveillance for Von-Hippel-Lindau disease.

Chantal R M Lammens1, Neil K Aaronson, Frederik J Hes, Thera P Links, Bernard A Zonnenberg, Jacques W M Lenders, Danielle Majoor-Krakauer, Theo A M Van Os, Encarna B Gomez-Garcia, Wouter de Herder, Rob B van der Luijt, Ans M W van den Ouweland, Liselot P Van Hest, Senno Verhoef, Eveline M A Bleiker.   

Abstract

PURPOSE: To assess compliance with a periodic surveillance regimen for Von Hippel-Lindau disease.
METHODS: In this nationwide study, Von Hippel-Lindau disease mutation carriers and those at 50% risk were invited to complete a questionnaire assessing (compliance with) advice given for periodic surveillance. Medical record data on compliance with recommended radiologic surveillance examinations were also collected.
RESULTS: Of the 84 (77%) participants, 78 indicated having received advice to undergo periodic surveillance. Of these, 71 reported being fully compliant with that advice. In 64% of the cases, this advice was only partially consistent with published guidelines. Based on medical record data, between one quarter and one third of individuals did not undergo surveillance as recommended in the guidelines for central nervous system lesions and one half for visceral lesions. Screening delay for central nervous system lesions was significantly higher in one hospital and in those cases where "the advice given" deviated from the guidelines.
CONCLUSIONS: The majority of those with or at risk of Von Hippel-Lindau disease reported having received and being fully compliant with screening advice. However, in many cases, the advice given was only partially consistent with published guidelines, and screening delays were observed. Efforts should be undertaken to stimulate guideline-based surveillance advice and to minimize screening delay.

Entities:  

Mesh:

Year:  2011        PMID: 21415761     DOI: 10.1097/GIM.0b013e3182091a1d

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  5 in total

1.  Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.

Authors:  Eliza Courtney; Xin Wei Chin; Jeanette Yuen; Shao-Tzu Li; Yanni Chen; John Carson Allen; Veronique Tan; Geok Hoon Lim; Joanne Ngeow
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

2.  Minors at risk of von Hippel-Lindau disease: 10 years' experience of predictive genetic testing and follow-up adherence.

Authors:  Roseline Vibert; Khadija Lahlou-Laforêt; Maryam Samadi; Valérie Krivosic; Thomas Blanc; Laurence Amar; Nelly Burnichon; Caroline Abadie; Stéphane Richard; Anne-Paule Gimenez-Roqueplo
Journal:  Eur J Hum Genet       Date:  2022-08-02       Impact factor: 5.351

3.  Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Authors:  Roeliene C Kruizinga; Denise M S van Marion; Wilfred F A den Dunnen; Jan C de Groot; Eelco W Hoving; Sjoukje F Oosting; Hetty Timmer-Bosscha; Rosalie P H Derks; Chantal Cornelissen; Rob B van der Luijt; Thera P Links; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

4.  The incidence of consecutive manifestations in Von Hippel-Lindau disease.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Roeliene C Kruizinga; Rachel S van Leeuwaarde; Rachel Giles; Maran J W Olderode-Berends; Thera P Links
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

5.  REPAIR OF COMBINED TRACTION-RHEGMATOGENOUS RETINAL DETACHMENT AFTER CRYOABLATION OF A RETINAL CAPILLARY HEMANGIOBLASTOMA.

Authors:  Philip J DeSouza; Craig M Greven
Journal:  Retin Cases Brief Rep       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.